FDCDDQ
XLO icon

Federation des caisses Desjardins du Quebec’s Xilio Therapeutics XLO Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-236
Closed -$2.78K – 3018
2025
Q3 		$2.78K Hold
236
– – ﹤0.01% 2562
2025
Q2 		$2.24K Hold
236
– – ﹤0.01% 2393
2025
Q1 		$2.39K Hold
236
– – ﹤0.01% 2308
2024
Q4 		$3.15K Buy
+236
New +$3.25K ﹤0.01% 2170

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's XLO Position: Q4 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 236 shares — an estimated $2.78K sold.

Federation des caisses Desjardins du Quebec first reported a position in XLO in Q4 2024 and held it in 4 quarters. The position peaked at $3.15K in Q4 2024. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 236 Xilio Therapeutics shares in Q4 2025, an estimated $2.78K.
  • Federation des caisses Desjardins du Quebec first reported a position in Xilio Therapeutics in Q4 2024 and held it in 4 quarters.
  • Federation des caisses Desjardins du Quebec's Xilio Therapeutics position peaked at $3.15K in Q4 2024.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2025, filed 12 Feb 2026.